Research Reports | Market Assessment
May 2022

Bladder Cancer And Upper Tract Urothelial Carcinoma – Current Treatment – Bladder Cancer | Current Treatment: Physician Insights | US

Table of contents

  • Bladder Cancer And Upper Tract Urothelial Carcinoma - Current Treatment - Bladder Cancer | Current Treatment: Physician Insights | US
    • Current Treatment Physician Insights Bladder Cancer US May 2022
Liseth Parra
Liseth Parra

Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.

Laura Vinuesa, D.V.M., M.Sc.
Laura Vinuesa, D.V.M., M.Sc.

Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports